YOMESAN ® is a Niclosamide based drug
THERAPEUTIC GROUP: Pesticide - anthelmintics, anticestodes
Indications YOMESAN ® Niclosamide
YOMESAN ® is indicated in the treatment of tapeworm infections such as Tenia saginata, Tenia solium, Diphyllobutrhium latum and others.
Mechanism of action YOMESAN ® Niclosamide
YOMESAN ® is an antiparasitic drug based on Niclosamide, an active ingredient with a strong tenicidal activity, and therefore successfully used against tapeworms responsible for infections in humans.
Taken orally, Niclosamide reaches the gastro-enteric environment unaltered where, in the absence of significant absorption, it concentrates, carrying out its therapeutic action on site through a molecular mechanism that is only partially clarified.
More precisely, this active principle seems to act at the level of the parasite's mitochondrion, blocking oxidative phosphorylation and inducing a serious energy depletion responsible for the death of the scholice, a primordial sketch of the adult parasite able to guarantee its adhesion to the intestinal mucosa, thus facilitating the subsequent increase of the proglottids.
The latter, imaginable as body segments but at the same time initiating elements of the biological cycle, in the absence of the schist, also useful for maintaining the trophic capacity of the parasite, are promptly attacked by intestinal lytic enzymes and thus eliminated through the faeces.
Studies carried out and clinical efficacy
NICLOSAMIDE IN THE CONTROL OF SCHISTOSOMIASIS
Ann Trop Med Parasitol. 2007 Sep; 101: 479-86.
Community acceptability of the use of low-dose niclosamide (Bayluscide), as a molluscicide in the control of human schistosomiasis in Sahelian Cameroon.
Takougang I, Meli J, Wabo Poné J, Angwafo F 3rd.
Clinical trial that defines the efficacy of Niclosamide, taken at low doses, in controlling the spread of schistosomiasis in areas where this parasitosis is evidently endemic.
THE ACTIVE NICLOSAMIDE AGAINST PSEUDOMONAS
Antimicrob Agents Chemother. 2013 Feb; 57: 996-1005.
New life for an old drug: the anthelmintic drug niclosamide inhibits Pseudomonas aeruginosa quorum sensing.
Imperi F, Massai F, Ramachandran Pillai C, Longo F, Zennaro E, Rampioni G, Visca P, Leoni L.
Work with a very high technological content which, with the help of Microarray, demonstrates how Niclosamide, in addition to having an evident and known anti-helminthic activity, can also present a potential anti-Pseudomonas Aeuriginosa action, evident with the impressive control activity against its gene expression.
POTENTIAL ANTI-CANCER ROLE OF NICLOSAMIDE
ACS Med Chem Lett. 2013 Feb 14; 4: 180-185. Epub 2013 Jan 15.
Discovery of O-Alkylamino Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents.
Chen H, Yang Z, Ding C, Chu L, Zhang Y, Terry K, Liu H, Shen Q, Zhou J.
Very recent study that demonstrates how some derivatives of Niclosamide can be, at least experimentally, effective in suppressing the proliferative rate of tumor cells.
Method of use and dosage
YOMESAN ®
500 mg Niclosamide tablets for oral use.
Niclosamide therapy, generally characterized by a short duration, should be defined by your doctor on the basis of the patient's age, his clinical picture and the type of parasite responsible for the infection.
Given the pharmaceutical form of YOMESAN ® it would be advisable to chew the tablet carefully, or dissolve it in a homogeneous solution before swallowing it, in order to optimize its therapeutic efficacy, potentially compromised by the abundant secretion of mucus induced by the parasite.
YOMESAN ® Niclosamide warnings
Before starting treatment with YOMESAN ®, in addition to requiring a careful medical consultation to evaluate all potential contraindications to the use of Niclosamide, it would be advisable to restore the correct fecal transit, in order to guarantee the correct elimination of the parasite.
In this regard, to facilitate the rapid evacuation of the cestode, a purgative could be combined with anthelmintic therapy, in order to avoid the continuous elimination of proglottids in the following days.
It would be advisable, together with the therapy, to implement all the hygiene rules useful to limit the spread of the parasite and in particular of pregnant proglottids, responsible for potential new biological cycles.
It is also important to remember that this drug is not effective against cysticercosis.
PREGNANCY AND BREASTFEEDING
Although the studies in the literature seem to agree on the absence of teratogenic and mutagenic effects of Niclosamide taken during pregnancy, in order to minimize the potential side effects it would be advisable to avoid taking the drug in the first trimester, considering all with your doctor. the potential risks and benefits.
It is clear that in case of unavoidable necessity, YOMESAN ® therapy should be carefully supervised by your gynecologist.
Interactions
There are currently no known drug interactions worthy of clinical note, other than those with alcohol, whose intake should be significantly limited during therapy.
Contraindications YOMESAN ® Niclosamide
The use of YOMESAN ® is contraindicated in case of hypersensitivity to the active substance or to one of its excipients.
Undesirable Effects - Side Effects
The use of YOMESAN ® is generally well tolerated and free from clinically relevant side effects.
Adverse reactions affecting the gastrointestinal tract and sometimes hypersensitivity reactions have only rarely been observed.
Note
YOMESAN ® is a prescription drug.
The information on YOMESAN ® Niclosamide published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.
